BR1010 in Patients With Essential Hypertension Patients Who do Not Adequately Respond to Fimasartan/Amlodipine Combination

Inclusion criteria

1.Voluntarily provided a written consent to participate in this clinical study 2.19 years old or above Koreans living in Korea 3.Patients with uncontrolled essential hypertension at screening time(Visit 1)

• Use antihypertensive drugs:140 mmHg ≤ sitSBP < 200 mmHg
• Naïve: 160 mmHg ≤ sitSBP < 200 mmHg 4.Patients with uncontrolled hypertension after Fimasartan/Amlodipine 30/5mg treatment for 4 weeks at randomization(Visit 2) (Selected Arm:140 mmHg ≤ sitSBP < 200 mmHg 5.Able to understand this study, be cooperative in the execution of the study, and participate in the study until its completion

Exclusion criteria

• Difference of SiSBP ≥ 20 mmHg and SiDBP ≥ 10 mmHg in 3 blood pressure measurements in the selected reference arm at the screening visit
• Blood pressure results showing sitDBP ≥ 120 mmHg at screening and baseline visit(Visit 1; Both Arm, Visit 2: Selected Arm)
• Treatment Compliance of Fimasartan/Amlodipine 30/5mg < 70%
• Heart failure(New York Heart Association class 3 and 4), ischemic heart disease, peripheral vascular disease
• Percutaneous Coronary Artery within 6 months prior to study
• Clinically significant ventricular tachycardia, atrial fibrillation, atrial flutter; or other arrhythmia conditions that are determined to be clinically significant by the investigator
• Patients who have history of severe cerebrovascular disease within 6 months prior to study
• Type I Diabetes Mellitus or Uncontrolled Type II Diabetes Mellitus(HbA1c > 9% at screening visit
• Patients who have history of severe or malignant retinopathy within 6 months prior to study
• Pregnant or lactating women
• Planning pregnancy during the study period or have childbearing potential but are not using acceptable contraceptive methods
• Patients taking other clinical trial drugs within 4 weeks from the time of visit for screening
• Patients who are judged unsuitable to participate in this study by investigator